肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979

2019-06-16 Allan 网络

REGN1979淋巴瘤CAR-T
关注

在欧洲血液学协会（EHA）会议上，Regeneron公司公布了针对B细胞标志物CD20和T细胞CD3的研究性双特异性单克隆抗体REGN1979治疗复发难治非霍奇金淋巴瘤（NHL）患者的最新结果，该项研究还包括两名经CAR-T治疗后疾病进展的复发难治DLBCL患者。结果显示，REGN1979疗效显著。

在欧洲血液学协会（EHA）会议上，Regeneron公司公布了针对B细胞标志物CD20和T细胞CD3的研究性双特异性单克隆抗体REGN1979治疗复发难治非霍奇金淋巴瘤（NHL）患者的最新结果，该项研究还包括两名经CAR-T治疗后疾病进展的复发难治DLBCL患者。结果显示，REGN1979疗效显著。

该试验涉及81例复发难治NHL患者，这些患者之前接受过抗CD20抗体治疗，其中45例患有DLBCL、21例患有滤泡性淋巴瘤（FL）、6例患有套细胞淋巴瘤、6例边缘区淋巴瘤和其他三种B-NHL亚型。患者入组后，每周接受REGN1979持续12周，然后每隔一周接受另外12周的剂量。Regeneron肿瘤学临床和转化科学负责人Israel Lowy指出：“我们将积极评估REGN1979在惰性和侵袭性非霍奇金淋巴瘤中的有效剂量”。


原始出处：

http://www.firstwordpharma.com/node/1647589#axzz5r0RYRQBl

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-10-04 仁者大医

    #CAR-#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-01-09 jinweidong

    #特异性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-19 marlenexl

    #细胞淋巴瘤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-18 xiaoyeshuang

    #B细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-18 hyf032

    #特异性抗体#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-17 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 04 14:57:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899299, encodeId=50071899299df, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 12:57:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Jun 19 12:57:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273309, encodeId=d48f12e330955, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526449, encodeId=996815264493c, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Jun 18 09:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367871, encodeId=e4cf36e87107, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jun 17 05:50:45 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367854, encodeId=c92836e854af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Sun Jun 16 19:17:24 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-16 orangesking

    看看

    0